CRY - Cryolife, Inc.


Weak GrowthStock Price Very High


based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 12.67%
Operating Income Growth is 365.85%
Net Income turning Positive
Earnings Per Share (EPS) turning Positive
Net Margin is 0.63%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 4.21
Debt Ratio is 0.62
Current Debt to Net Income Ratio is 0.16
Total Debt to Total Assets Ratio is 0.39
Cash Flow is WEAK
Cash from Operations Growth is -73.07%
Capital Expenditure is High
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Cryolife, Inc. (CRY) -
Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - James Mackin
Employees - 1,200

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.